Advertisement

Topics

Eisai Europe Ltd Company Profile

02:36 EDT 20th September 2018 | BioPortfolio

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic area for Eisai in the European market.


News Articles [317 Associated News Articles listed on BioPortfolio]

Eisai/MSD’s Lenvima approved in Europe for liver cancer

Eisai and MSD’s Lenvima has won approval in the US as a first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).

Oncodesign Furthers Its Cooperation with Eisai, Started 12 Years Ago

Signature of a new services agreement on breast cancer with the Japanese pharmaceutical company Eisai This program's objective is to define the clinical positioning strategy of Eisai new compounds...

UPDATE 1-Merck, Eisai sign deal to further develop, sell Eisai cancer drug

Merck & Co Inc and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in d...

Merck, Eisai in deal to further develop, sell Eisai cancer drug

NEW YORK (Reuters) - Merck & Co Inc and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already appr...

Merck, Eisai sign deal to further develop, sell Eisai cancer drug

(Reuters) - Merck & Co and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in many ...

Eisai: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment "GOOFICE 5mg Tablet" Published in The Lancet Gastroenterology & Hepatology

TOKYO, July 9, 2018 - (JCN Newswire) - Eisai Co., Ltd., Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce that results from two phas...

Eisai Plans Invests $100M in Genetics Guided Dementia Discovery Facility in Cambridge, Mass.

Eisai Inc. is adding to its arsenal aimed at combating dementia. The company will launch the Eisai Center for Genetics Guided Dementia Discovery.

Eisai's LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea

TOKYO, Aug 30, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that its South Korea subsidiary Eisai Korea Inc. received approval for the kinase inhibitor LENVIMA (lenvatinib mesylate) as a singl...

Drugs and Medications [15 Associated Drugs and Medications listed on BioPortfolio]

Halaven [Eisai Inc.]

These highlights do not include all the information needed to use HALAVEN™ safely and effectively. See full prescribing information for HALAVEN. HALAVEN™ (eribulin mesylate) Injection For intraven...

Lusedra [Eisai, Inc]

These highlights do not include all the information needed to use LUSEDRA safely and effectively. See full prescribing information for LUSEDRA. LUSEDRA (fospropofol disodium) Injection, for intravenou...

Ontak [Eisai, Inc]

These highlights do not include all the information needed to use Ontak safely and effectively. See full prescribing information for Ontak. ONTAK (denileukin diftitox) Injection for intravenous infusi...

Hexalen [Eisai Inc.]

HEXALEN (ALTRETAMINE) CAPSULES 50 mg R Only

Targretin [Eisai Inc.]

Targretin® (bexarotene) capsules, 75 mg

PubMed Articles [342 Associated PubMed Articles listed on BioPortfolio]

The genomic history of southeastern Europe.

Farming was first introduced to Europe in the mid-seventh millennium bc, and was associated with migrants from Anatolia who settled in the southeast before spreading throughout Europe. Here, to unders...

Towards the risk of Yellow Fever transmission in Europe.

Yellow fever (YF) is an emerging expanding fatal arboviral disease that has been imported at least six times in Europe during the first half of 2018, while only seven travel-associated YF cases have b...

Infectious disease profiles of Syrian and Eritrean migrants presenting in Europe: A systematic review.

In the past decade, a large influx of migrants presented in Europe. Their country of origin was mainly either Syria or Eritrea. Public health institutions in host countries in Europe are challenged to...

The removal of DAA restrictions in Europe - one step closer to eliminating HCV as a major public health threat.

Of ∼10.2 million people with chronic HCV infection in Europe, most are living in Eastern Europe (6.7 million) followed by Western Europe (2.3 million) and Central Europe (1.2 million). HCV transmiss...

The evolutionary history of human populations in Europe.

I review the evolutionary history of human populations in Europe with an emphasis on what has been learned in recent years through the study of ancient DNA. Human populations in Europe ∼430-39kya (a...

Clinical Trials [603 Associated Clinical Trials listed on BioPortfolio]

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials

This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.

In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study

This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.

Description/Characterisation of Asthmatics Eligible for Biologic Therapy Referral in Prim. and Sec. Care in Europe

This is a multi-country, multicentre, observational cross-sectional one-visit study of patients with severe asthma in primary and secondary care settings in Europe

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

This multicenter, prospective, single-arm, phase 3 study will assess the proportion of disease-free patients, starting from administration of the first study treatment to at least 12-month...

EUROpE-RSI (EURopean Online Evaluation RSI Study)

The investigators want to identify and show differences in standards and procedures of in-hospital rapid sequence induction by collecting data with an online survey for anaesthetist in Eur...

Companies [857 Associated Companies listed on BioPortfolio]

Eisai Europe Limited

Eisai is committed to making further contributions to addressing the diversified needs and improving quality of life of patients with epilepsy. Eisai has three currently marketed treatments in Eur...

Eisai Europe Ltd

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic ar...

Eisai GmbH

Auf dem globalen Pharmamarkt zählt Eisai zu den führenden forschungs- orientierten Pharmaunternehmen. Mit innovativen Präparaten für Erkrankungen des Zentralen Nerven- systems sowie im Magen-Darm-...

Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Res...

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facili...

More Information about "Eisai Europe Ltd" on BioPortfolio

We have published hundreds of Eisai Europe Ltd news stories on BioPortfolio along with dozens of Eisai Europe Ltd Clinical Trials and PubMed Articles about Eisai Europe Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eisai Europe Ltd Companies in our database. You can also find out about relevant Eisai Europe Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...


Corporate Database Quicklinks



Searches Linking to this Company Record